sábado, 22 de noviembre de 2025

FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario